(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...
Background: Respiratorysyncytialvirus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...
Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...
released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (RespiratorySyncytialVirus Vaccine) when co ...
Some results have been hidden because they may be inaccessible to you